Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime® a Product Used to Diagnose Intra-Abdominal Infection and Inflammatory Bowel Disease
January 26, 2020 – Jubilant Radiopharma, a business unit of Jubilant Pharma Limited, announced today that they received approval from Health Canada for Drax Exametazime (Kit for the Preparation of Tc99m Exametazime for leukocyte labeling). Leukocyte labeling scintigraphy is a nuclear medicine imaging procedure that helps physicians localize intra-abdominal infection and inflammatory bowel disease.
When a patient is imaged using a gamma camera (a special diagnostic imaging camera used in nuclear medicine), physicians are able to see the accumulation of radioactive leukocytes (or white blood cells) in the pelvic and abdominal regions. If the accumulation of leukocytes is seen in the pelvic or abdominal area, about 4 hours after injection of the radioactive labeled leukocytes, the physician can determine if there is inflammatory bowel disease or infection. Alternatively, normal gastrointestinal transit is diagnosed when the accumulation of leukocytes clears from the pelvic or abdominal area, as seen on the initial images. Understanding both potential outcomes of the procedure is important for proper image interpretation and patient management.
“This recent Health Canada approval further demonstrates the continued commitment by Jubilant Radiopharma to advance the field of nuclear medicine and supports our company’s ongoing mission to Improve Lives through Nuclear Medicine,” commented Sergio Calvo, Radiopharmaceuticals Division President. “Jubilant Radiopharma is committed to providing healthcare professionals the highest quality radiopharmaceuticals and dependable advanced technologies designed to enable better patient outcomes across the globe.”
For more information Drax Exametazime click here